The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa

Journal of Infection and Chemotherapy

Volumn 14, Issue 3, 2008, Pages 219-222

  Harashima, Shin Ichi ^a,c   Kondo, Hiroko ^a   Nabeshima, Atsuko ^a   Shimoda, Masako ^a   Yamaji, Kouzaburo ^a   Horiuchi, Takahiko ^b   Shimono, Nobuyuki ^b   Ikematsu, Hideyuki ^a  

^a Hara Doi Hospital   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Drug resistance; Geriatric patient; Meropenem; Nosocomial infection; Pharmacokinetics Pharmacodynamics; Pseudomonas aeruginosa

Indexed keywords

IMIPENEM; MEROPENEM;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PNEUMONIA; PSEUDOMONAS AERUGINOSA;

EID: 45749143589     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-008-0601-8     Document Type: Article

References (18)

1. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
2. Kollef MH. Gram-negative bacterial resistance. Evolving patterns and treatment paradigms. Clin Infect Dis 2005;40:85-88.
3. Pitten FA, Panzig B, Schröder G, Tietze K, Kramer A. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German university hospital 2001;47:125-130.
4. Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechovsky N. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. J Hosp Infect 1998;39:53-62.
5. Ikematsu H, Yamaga S, Nabeshima A, Yamaji K, Kakuda K, Ueno K, et al. Incidence and duration of febrile episodes in a hospitalized geriatric cohort. J Jpn Assoc Infect Dis 1996;70:1079-1085.
6. Ikematsu H, Nabeshima A, Yamaga S, Yamaji K, Kakuda K, Ueno K, et al. Serum albumin level as a predictor of incidence of febrile episodes and mortality in hospitalized geriatric patients. J Jpn Assoc Infect Dis 1996;70:1259-1265.
7. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infec Dis 2004;38:670-677.
8. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa 1999;28:1128-1133.
9. Centers for disease control and prevention. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 to June 2001. Am J Infect Control 2001;29:404-421.
10. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotics susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups, JAMA 1999;281:67-71.
11. Kollef MH. Appropriate empiric antimicrobial pneumonia: the role of the carbapenems. Respiratory Care 2004;49:1530-1541.
12. Kollef MH. Appropriate empirical antibacterial infections. Drugs 2003;63:2157-2168.
13. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationalefor antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
14. Kotapati S, Nicolau DP, Nightingale CH, Kuti JL. Clinical and economic benefits of meropenem dosage strategy based on pharmacodynamic concepts. Am J Health-Syst Pharm 2004;61:1264-1270.
15. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in health volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother 2003;52:518-521.
16. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003;23:988-991.
17. Mikamo H. The proper use of carbapenem examined by Monte Carlo simulation. Jpn J Antibiotics. 2005;58:359-367.
18. Kawano S, Matsushima T, Saito A, Nakata K, Yamaguchi K, Watanabe S, et al, editors. The JRS guidelines for the management of community-acquired pneumonia in adults. Tokyo: The Japanese Respiratory Society; 2007, p. 1-57.